AirXpanders is a technology company.
AirXpanders has raised $31.0M across 4 funding rounds.
AirXpanders has raised $31.0M in total across 4 funding rounds.
AirXpanders, Inc. was a medical device company that developed the AeroForm Tissue Expander System, a needle-free, patient-controlled device for two-stage breast reconstruction following mastectomy.[1][2][3] It served breast cancer patients and surgeons, solving the problem of painful, frequent saline injections by enabling at-home CO2 expansion via a wireless controller, reducing clinic visits and improving patient control.[1][2][6] The company achieved FDA clearance in 2016 and 2017, CE Mark in Europe (2012), and TGA approval in Australia, with commercial availability there, but ceased operations in 2019 amid financial challenges after raising $46.18M and going public via IPO in 2015.[2][3]
Founded in 2005 and headquartered in San Jose, California (with some sources noting San Francisco), AirXpanders emerged to innovate in breast reconstruction by replacing traditional saline-filled expanders with a patient-controlled alternative.[1][2][3] The idea stemmed from addressing the limitations of weekly surgeon visits for injections, leading to the AeroForm system's development as the first FDA-cleared needle-free option using CO2.[1][2] Early milestones included CE Mark in 2012, Australian commercialization, FDA de novo authorization in 2016, and full U.S. clearance in 2017, alongside recognition like Popular Science's "Best of What's New."[3][5] It listed on the ASX (AXP) and pursued U.S. launch, but financial pressures culminated in workforce cuts and shutdown in July 2019.[3]
AirXpanders rode the trend toward patient-centric medical devices in reconstructive surgery, capitalizing on rising mastectomy rates and demand for less invasive breast reconstruction post-cancer treatment.[1][2] Timing aligned with FDA's de novo pathway for novel devices and growing adoption of wireless health tech, amid market forces like healthcare efficiency pressures and women's health innovation.[2][3][6] It influenced the ecosystem by pioneering needle-free expansion, inspiring competitors in tissue expansion and contract manufacturing (e.g., C2C), though its 2019 closure highlighted commercialization risks for medtech startups in low-volume, high-regulation segments.[2][3]
AirXpanders' legacy is its pioneering AeroForm, which demonstrated viable needle-free reconstruction but faltered on commercialization sustainability, leading to Chapter 7 bankruptcy in 2019.[3] No active operations exist today; its IP or technology may have been acquired post-liquidation, potentially reviving in a consolidated medtech landscape. Future trends like AI-driven personalization and telehealth could reshape similar innovations, but AirXpanders underscores execution risks in patient-controlled devices—echoing its original mission to lead reconstructive surgery standards.[1][2][3]
AirXpanders has raised $31.0M in total across 4 funding rounds.
AirXpanders's investors include Frazier Healthcare Partners, Vivo Capital.
AirXpanders has raised $31.0M across 4 funding rounds. Most recently, it raised $1.0M Series E in September 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2014 | $1.0M Series E | Frazier Healthcare Partners, Vivo Capital | |
| Jun 1, 2013 | $9.0M Series E | Frazier Healthcare Partners, Vivo Capital | |
| Apr 1, 2012 | $11.0M Series D | Frazier Healthcare Partners, Vivo Capital | |
| Jan 1, 2012 | $10.0M Series D | Frazier Healthcare Partners, Vivo Capital |